Objective: To observe the effect of combined therapy regimen on ovarian function, MMP and related factors in patients with adenomyosis under the condition of LNG-IUS drug therapy. Methods: A total of 110 patients with...Objective: To observe the effect of combined therapy regimen on ovarian function, MMP and related factors in patients with adenomyosis under the condition of LNG-IUS drug therapy. Methods: A total of 110 patients with adenomyosis from October 2015 to October 2017 were retrospectively analyzed and divided into control group and observation group. The control group of 54 patients, observation group of 56 patients. All patients were treated with LNG-IUS system in the 4th to 7th day of the menstrual cycle. The patients in the observation group were treated with TCRE on the basis of LNG-IUS. The fasting venous blood was taken from the third day of menstruation and the luteinizing hormone (LH (MMP-2, MMP-3, MMP-9) were detected by enzyme-linked immunosorbent assay (ELISA). The levels of VEGF, CA125 and IGF-1 were detected by enzyme-linked immunosorbent assay (ELISA) Ang-2, PGE2 levels were compared. Results: There was no significant difference in LH, FSH and E2 levels between the two groups before treatment. After treatment, the levels of LH, FSH and E2 were significantly higher in the two groups compared with those before treatment. (2) Before treatment, the levels of serum MMP-2, MMP-3, MMP-2 and MMP-2 in the two groups were significantly higher than those in the control group. The levels of MMP-2, MMP-3 and MMP-9 in the serum of the two groups were significantly lower than those before treatment, and there was no significant difference between the two groups. (3) Before treatment, serum levels of VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those in the control group. The levels of serum VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those before treatment. The patients in the observation group were significantly lower than the control group, there was significant difference between the two groups. Conclusion The levels of serum MMP-2, MMP-3, MMP-9 and VEGF, CA125, IGF-1, Ang-2 and MMP-2 in patients with adenomyosis were treated with TCRE on the basis of LNG-IUS drug therapy. PGE2 level, indicating that TCRE combined with LNG-IUS drug therapy can not only improve the efficacy, improve the patient's menstrual flow, dysmenorrhea and other symptoms, control the progression of the disease, but also by regulating the expression of certain factors play a role in improving ovarian function, worthy of clinical On the promotion and application.展开更多
目的探讨宫腔镜子宫内膜切除术（transcervical resection of endometrium,TCRE）治疗子宫腺肌病的手术指征及疗效。方法对2004年11月-2007年10月因子宫腺肌病接受TCRE的31例临床资料进行回顾性分析,比较术前后痛经缓解率、月经量、血Hb...目的探讨宫腔镜子宫内膜切除术（transcervical resection of endometrium,TCRE）治疗子宫腺肌病的手术指征及疗效。方法对2004年11月-2007年10月因子宫腺肌病接受TCRE的31例临床资料进行回顾性分析,比较术前后痛经缓解率、月经量、血Hb、CA125水平。结果31例TCRE手术时间（14.4±1.4）min（10-28min）,术中出血量10-50ml。术后随访24-48个月,痛经缓解有效率93.5%（29/31）,2例痛经不能缓解,且子宫进行性增大,1例行全子宫切除术,另1例服用孕三烯酮仍在随访中。1例术后11个月宫腔粘连致宫腔积血,行宫腔扩创引流积血约10ml痊愈。月经量由术前（102.0±4.7）ml减少至术后（15.6±2.1）ml（t=223.77,P=0.000）,其中闭经7例,点滴状月经18例,月经量显著减少6例。22例术后3个月内贫血纠正,血红蛋白由术前（78.6±3.6）g/L上升至（126.8±8.9）g/L（t=-27.953,P=0.000）。术后血清CA125除2例持续〉35IU/ml,其余术后3个月降至正常范围。结论TCRE治疗子宫腺肌病能有效缓解痛经症状,治疗贫血,但术前应排除盆腔子宫内膜异位症,子宫大小≤8孕周。展开更多
文摘Objective: To observe the effect of combined therapy regimen on ovarian function, MMP and related factors in patients with adenomyosis under the condition of LNG-IUS drug therapy. Methods: A total of 110 patients with adenomyosis from October 2015 to October 2017 were retrospectively analyzed and divided into control group and observation group. The control group of 54 patients, observation group of 56 patients. All patients were treated with LNG-IUS system in the 4th to 7th day of the menstrual cycle. The patients in the observation group were treated with TCRE on the basis of LNG-IUS. The fasting venous blood was taken from the third day of menstruation and the luteinizing hormone (LH (MMP-2, MMP-3, MMP-9) were detected by enzyme-linked immunosorbent assay (ELISA). The levels of VEGF, CA125 and IGF-1 were detected by enzyme-linked immunosorbent assay (ELISA) Ang-2, PGE2 levels were compared. Results: There was no significant difference in LH, FSH and E2 levels between the two groups before treatment. After treatment, the levels of LH, FSH and E2 were significantly higher in the two groups compared with those before treatment. (2) Before treatment, the levels of serum MMP-2, MMP-3, MMP-2 and MMP-2 in the two groups were significantly higher than those in the control group. The levels of MMP-2, MMP-3 and MMP-9 in the serum of the two groups were significantly lower than those before treatment, and there was no significant difference between the two groups. (3) Before treatment, serum levels of VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those in the control group. The levels of serum VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those before treatment. The patients in the observation group were significantly lower than the control group, there was significant difference between the two groups. Conclusion The levels of serum MMP-2, MMP-3, MMP-9 and VEGF, CA125, IGF-1, Ang-2 and MMP-2 in patients with adenomyosis were treated with TCRE on the basis of LNG-IUS drug therapy. PGE2 level, indicating that TCRE combined with LNG-IUS drug therapy can not only improve the efficacy, improve the patient's menstrual flow, dysmenorrhea and other symptoms, control the progression of the disease, but also by regulating the expression of certain factors play a role in improving ovarian function, worthy of clinical On the promotion and application.
文摘目的探讨宫腔镜子宫内膜切除术（transcervical resection of endometrium,TCRE）治疗子宫腺肌病的手术指征及疗效。方法对2004年11月-2007年10月因子宫腺肌病接受TCRE的31例临床资料进行回顾性分析,比较术前后痛经缓解率、月经量、血Hb、CA125水平。结果31例TCRE手术时间（14.4±1.4）min（10-28min）,术中出血量10-50ml。术后随访24-48个月,痛经缓解有效率93.5%（29/31）,2例痛经不能缓解,且子宫进行性增大,1例行全子宫切除术,另1例服用孕三烯酮仍在随访中。1例术后11个月宫腔粘连致宫腔积血,行宫腔扩创引流积血约10ml痊愈。月经量由术前（102.0±4.7）ml减少至术后（15.6±2.1）ml（t=223.77,P=0.000）,其中闭经7例,点滴状月经18例,月经量显著减少6例。22例术后3个月内贫血纠正,血红蛋白由术前（78.6±3.6）g/L上升至（126.8±8.9）g/L（t=-27.953,P=0.000）。术后血清CA125除2例持续〉35IU/ml,其余术后3个月降至正常范围。结论TCRE治疗子宫腺肌病能有效缓解痛经症状,治疗贫血,但术前应排除盆腔子宫内膜异位症,子宫大小≤8孕周。
